SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 151 filers reported holding SAGE THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $293,000 | -14.3% | 6,602 | +9.6% | 0.01% | -25.0% |
| Q2 2021 | $342,000 | +2.1% | 6,026 | +34.5% | 0.01% | +14.3% |
| Q1 2021 | $335,000 | -16.9% | 4,481 | -3.9% | 0.01% | -12.5% |
| Q4 2020 | $403,000 | +30.8% | 4,663 | -7.5% | 0.01% | 0.0% |
| Q3 2020 | $308,000 | +48.8% | 5,042 | +1.1% | 0.01% | +33.3% |
| Q2 2020 | $207,000 | -31.2% | 4,986 | -50.1% | 0.01% | -73.9% |
| Q2 2016 | $301,000 | -60.0% | 10,000 | -33.3% | 0.02% | -30.3% |
| Q1 2015 | $753,000 | – | 15,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |